Zoetis (ZTS) Acquisitions (2015 - 2022)

Zoetis' (ZTS) quarterly Acquisitions came in at $215.0 million in Q3 2022, down 88.59% on a QoQ basis from $1.9 billion in Q3 2018.

Zoetis (ZTS) Acquisitions (2015 - 2022) Analysis & Trends

Zoetis (ZTS) has 5 years of Acquisitions data on file, last reported at $215.0 million in Q3 2022.

On a quarterly basis, Acquisitions changed N/A year-over-year to $215.0 million in Q3 2022; TTM through Sep 2022 was $215.0 million, a N/A change from a year earlier, with the FY2018 full-year figure at $1.9 billion, changed N/A from the prior year.
Acquisitions for Q3 2022 stood at $215.0 million, down from $1.9 billion in the prior quarter.
Over the last five years, Acquisitions for ZTS reached as high as $1.9 billion in Q3 2018 and fell as low as $215.0 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Vireo Growth	10.57 Bn	10.41 Bn	59.30 Mn	-18.20 Mn

Download Data